Stock Analiz

Geron Corp. GERN

Biotechnology: Pharmaceutical Preparations · IPO 1996 · data as of November 13, 2026

$0.97Market cap $623M
Open the interactive analysis →

Geron Corp. (GERN) is a healthcare company listed in the US with a market value of about $623M. In the twelve months to September 30, 2026 it had revenue of $218M and net income of -$48M, a net margin of -22.0%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -45%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.

About Geron

Geron is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 1996. Revenue went from $1M in 2014 to $237000 in 2023, a decline of about 16.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 75% over three years (dilution for shareholders).

Score: 0.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E14.9
P/FCF—
P/S2.9
P/B2.7
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-14.6%
Shareholder yield0.0%
Intrinsic value vs. price−59%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-36611.7%
ROIC (5-yr avg.)-44.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$218M——$237000$596000$1M$253000$460000$1M$1M$6M
Net income-$48M-$84M-$175M-$184M-$142M-$116M-$76M-$69M-$27M-$28M-$30M
Free cash flow-$91M—-$219M-$169M-$128M-$96M-$67M-$44M-$21M—-$18M
EPS (diluted)$-0.08$-0.13$-0.27$-0.32$-0.37$-0.35$-0.28$-0.36$-0.15$-0.18$-0.19
Net margin-22.0%——-77690.7%-23808.9%-8335.4%-29888.1%-14901.7%-2534.4%-2621.2%-479.3%
ROIC—-13.4%-34.1%-45.9%-80.6%-49.6%-25.2%-41.6%-13.8%-22.3%-19.8%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $3.50, 262% above the current price; targets range from $2.50 to $5.00; the consensus rating is “Buy”; expected EPS is $-0.02 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Geron stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Geron pay a dividend?

Not currently.

Is Geron a good stock to buy?

We do not give buy or sell advice. Geron scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.